ARTA
IMNP

A.R.T. Advisors’s Immune Pharmaceuticals Inc. IMNP Stock Holding History

A.R.T. Advisors’s Portfolio IMNP Stock Details IMNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-520
Closed -$18K – 1852
2015
Q1 		$18K Buy
520
+10
+2% +$374 ﹤0.01% 1386
2014
Q4 		$19K Buy
+510
New +$27.4K ﹤0.01% 1375

Other funds holding IMNP

PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
EEG
E.E. Geduld $178M AUM 29.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
IFS
Ifrah Financial Services Little Rock, Arkansas $409M AUM 28.15% 1-Year Est. Return
BPCE
Bank Pictet & Cie (Europe) Frankfurt Am Main, Germany $5.12B AUM 27.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

A.R.T. Advisors's IMNP Position: Q2 2015 in Review

A.R.T. Advisors sold out of Immune Pharmaceuticals Inc. (IMNP) in Q2 2015, closing a stake of 520 shares — an estimated $18K sold.

A.R.T. Advisors first reported a position in IMNP in Q4 2014 and held it in 2 quarters. The position peaked at $19K in Q4 2014. 12 funds tracked by Wall St. Rank hold IMNP as of Q2 2015.

  • A.R.T. Advisors reported no remaining Immune Pharmaceuticals Inc. position as of Q2 2015 after selling out during the quarter.
  • A.R.T. Advisors sold 520 Immune Pharmaceuticals Inc. shares in Q2 2015, an estimated $18K.
  • A.R.T. Advisors first reported a position in Immune Pharmaceuticals Inc. in Q4 2014 and held it in 2 quarters.
  • A.R.T. Advisors's Immune Pharmaceuticals Inc. position peaked at $19K in Q4 2014.
  • 12 funds tracked by Wall St. Rank held Immune Pharmaceuticals Inc. as of Q2 2015.

Based on A.R.T. Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.